Apalutamide and Overall Survival in Prostate Cancer

2020284 citationsJournal Articlehybrid Open Access

Authors

Matthew R. Smith · Massachusetts General Hospital

Fred Saad · Centre Hospitalier de l’Université de Montréal

Simon Chowdhury · King's College Hospital

Stéphane Oudard

Boris Hadaschik · University of Duisburg-Essen

Julie N. Graff · VA Portland Health Care System

David Olmos · Instituto de Investigación Biomédica de Málaga

Abstract

With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Urology

Volume 79, Issue 1, pp. 150-158

DOI: 10.1016/j.eururo.2020.08.011

Field-Weighted Citation Impact: 21.01